South Africa covid-19 vaccine prevention South Africa

AstraZeneca vaccine doesn't prevent B1351 COVID in early trial

Reading now: 609
www.cidrap.umn.edu

Two doses of the AstraZeneca-Oxford University COVID-19 vaccine were ineffective against mild-to-moderate infections with the B1351 variant first identified in South Africa, according to a phase 1b-2 clinical trial published today in the New England Journal of Medicine.The double-blind multicenter study, led by scientists at the South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, studied the safety and the efficacy of the AstraZeneca ChAdOx1 nCoV-19 vaccine in HIV-negative adults aged 18 to 64 who received either two standard doses of the vaccine or a placebo in a 1:1 ratio 21 to 35 days apart from Jun 24 to Nov 9, 2020.

Read more on cidrap.umn.edu
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA